Baxter Intl Inc Stock Price, News & Analysis

Baxter International reported a 9% increase in third-quarter revenue, reaching $3.2 billion, driven by strong sales across all geographic segments. U.S. GAAP earnings per share rose 29% to $0.89, while adjusted EPS increased by 23% to $1.02. Baxter anticipates full-year sales growth of 7%-8% and adjusted EPS between $3.58 and $3.62. The company announced the acquisition of Hillrom, aiming to enhance its product portfolio and innovation pipeline. Additionally, Baxter launched new medical products and received FDA approval for premix Norepinephrine Bitartrate injection.

Baxter and bioMérieux have announced the CE marking of the NEPHROCLEAR™ CCL14 Test, a diagnostic tool designed to predict persistent severe acute kidney injury (PS-AKI). Expected for commercial launch in western Europe in 2022, the test aims to optimize critical care by helping healthcare providers anticipate the appropriate level of care for AKI patients. CCL14 has been identified as the most predictive biomarker for PS-AKI, with a diagnostic accuracy (AUC) of 0.82, indicating its potential to significantly improve patient outcomes.

Baxter International Inc. (NYSE:BAX) will present at the Credit Suisse 30th Annual Virtual Healthcare Conference on November 8, 2021, at 8:50 a.m. ET.

The presentation by CFO Jay Saccaro will be accessible via a live webcast on www.baxter.com and available for replay until November 7, 2022. Baxter, a global leader in medical products, serves millions of patients daily across over 100 countries, focusing on critical care, nutrition, and renal products. For more information, visit their website.

Baxter International Inc. (NYSE:BAX) presented critical care study findings at the 34th Annual European Society of Intensive Care Medicine (ESICM) LIVES virtual congress from Oct. 3-6, 2021. The data emphasized personalized healthcare approaches for patients with acute kidney injury (AKI) or sepsis. A study revealed the prevalence of persistent severe AKI (PS-AKI) among hospitalized adults, significantly increasing mortality risks. Additionally, findings from the FRESH clinical trial indicated that dynamic fluid management may improve kidney function in septic patients. Baxter also organized symposia on digital transformation and fluid management.

Baxter International Inc. (NYSE:BAX) will host a conference call on October 28, 2021, at 7:30 a.m. Central Time to discuss its third-quarter 2021 financial results. Participants can pre-register using the provided link or access the call via webcast on Baxter's website. With over 85 years in the industry, Baxter continues to offer critical care, nutrition, and surgical products globally. The meeting underscores Baxter's commitment to transparency and investor communication as it prepares to share key financial insights.

Baxter International Inc. (NYSE:BAX) has received FDA approval for its premix Norepinephrine Bitartrate in 5% Dextrose Injection, the first ready-to-use formulation of norepinephrine, which is crucial for treating severe hypotension in adults. Available in 4 mg/250 mL and 8 mg/250 mL concentrations, this formulation enhances patient safety by reducing compounding errors and offers flexible storage options, including room temperature. The product features a shelf life of up to 21 months in refrigeration and up to 90 days at room temperature, utilizing Baxter's proprietary VIAFLO container technology.

Baxter International has announced its acquisition of Hillrom for $156.00 per share, totaling $10.5 billion in cash. This strategic move aims to enhance access to care and accelerate digital health solutions globally. The acquisition is expected to generate approximately $250 million in annual pre-tax cost synergies by year three, with a positive impact on Baxter's adjusted earnings per share (EPS) projected to exceed 20% by year three. Both companies' boards have unanimously approved the deal, which is set to close by early 2022.

The Baxter International Foundation has partnered with UNICEF USA to enhance access to safe water in La Guajira, Colombia, through a $1.5 million grant. This three-year initiative aims to benefit thousands of children and families by improving water, sanitation, and hygiene (WASH) services via rehabilitation, education, and collaboration. With alarming statistics indicating a significant lack of access to clean water, this project will include rehabilitating water systems and distributing hygiene kits. Baxter's long-standing commitment to community health aligns with this initiative's goal of supporting sustainable access to clean water.

Baxter International Inc. (NYSE:BAX) is advancing its digital transformation by focusing on three areas: enhancing digital health solutions, improving customer experiences, and modernizing technology capabilities. Collaborating with Amazon Web Services, Baxter is moving its data centers to the cloud, which has led to increased speed, geographical expansion, and cost savings. This transformation supports its digital health solutions, including the Sharesource remote patient management platform for home dialysis, and enhances its supply chain resilience amid global challenges. The company is also investing in employee digital training.